key: cord-0892774-5fpxpram authors: Atienza-Diez, I.; Seoane, L. F. title: Long- and short-term effects of cross-immunity in epidemic dynamics date: 2022-04-05 journal: nan DOI: 10.1101/2022.04.04.22273361 sha: fda1635a864019e33985c23796755ff15ca7b9f2 doc_id: 892774 cord_uid: 5fpxpram The vertebrate immune system is capable of strong, focused adaptive responses that depend on T-cell specificity in recognizing antigenic sequences of a pathogen. Recognition tolerance and antigenic convergence cause cross-immune reactions that extend prompt, specific responses to rather similar pathogens. This suggests that reaching herd-immunity might be facilitated during successive epidemic outbreaks (e.g., SARS-CoV-2 waves with different variants). Qualitative studies play down this possibility because cross-immune protection is seldom sterilizing. We use minimal quantitative models to study how cross-immunity affects epidemic dynamics over short and long timescales. In the short scale, we investigate models of sterilizing and attenuating immunity, finding equivalences between both mechanisms---thus suggesting a key role of attenuating protection in achieving herd immunity. Our models render maps in epidemic-parameter space that discern threatening variants depending on acquired cross-immunity levels. We illustrate this application with SARS-CoV-2 data, including protection due to vaccination rates across countries. In the long-time scale, we model sterilizing cross-immunity between rolling pathogens to characterize statistical properties of successful strains. We find that sustained cross-immune protection alters the regions of epidemic-parameter space where large outbreaks happen. Our results suggest an optimistic revision concerning prospects for herd protection based on cross-immunity, including for the SARS-CoV-2 pandemics. Responding to threats, the immune system triggers defenses of different specificity, over different time scales [1] . An innate immunity prompts a quick, general response against any invading pathogen. It performs non-specific tasks such as recruiting immune cells to the infection site, identifying and removing foreign substances, and initiating adaptive immunity by presenting antigens to T-cells. This adaptive immunity, in turn, is much more specific and long-lasting. T-cells learn to identify the presented pathogen, which will henceforth be neutralized when encountered. Memory gained by T-cells can last a life-time and is rather specific. As a pathogen mutates, its antigenic sequences change. If this happens too quickly, strains generated within an infected host can shortly become unrecognizable by Tcells. During acute HIV infection, systemic failure occurs when too many variants overwhelm the immune system [2, 3] . A similar drifting mechanism accounts for new, yearly strains of flu virus-but its slower evolutionary pace results in new variants over the extended host population, not within each infected individual. Some crossimmunity remains depending on how much each strain has diverged from its ancestor. Historic trends of deaths due to influenza show this mechanism at work [4] : This virus evolves within a cluster of fairly similar strains for years. During such periods, the immunity gained against the cluster founder offers partial protection-decreased * Corresponding author, brigan@gmail.com. mortality is observed. Sporadically, the dominant strain differs enough and cross-immunity dwindles. This new, distant variant causes much larger mortality, then starts a new cluster that dominates for the next cycles. Cross-immunity impacts epidemic dynamics at many levels. Can we describe mathematically how it alters the unfolding of two consecutive, related outbreaks? Can these effects help a population achieve herd immunity faster? Cross-reactive protection can also happen beyond immediately related strains-even across different viruses, if they share or converge upon domains of antigenic sequences [5] [6] [7] [8] . At larger scales, how does crossimmunity change overall statistical properties of recurring epidemics? How much drift can we expect between strains that cause large pandemics? And between variants causing smaller outbreaks? How are these properties affected by a population's lasting immune memory? We tackle these questions using compartmental epidemiological models. The first, simplest such model, SIR, was introduced by Kermack and McKendrick in 1927 [9] . They divided a host population into: S, for susceptible; I, for infected; and R, for removed. Infected individuals recover spontaneously (I → R) at a rate γ. Susceptible hosts become infected (S → I) at a rate β, the pathogen's infectivity. This model initially portrays either a decaying or rising number of infections, depending on whether the susceptible population is below or above a threshold. In the second case, as the susceptible compartment is consumed, a spontaneous decay ensues after the model's threshold is reached-resulting in the characteristic SIR peak. In this model, individuals that moved into the recovered compartment become immunized. This is the origin of herd immunity-protected Seeking simplest models of cross-immunity. We depart from the SIR equations and attempt to modify them as little as possible to study cross-immunity between successive variants of a pathogen. a Model with sterilizing immunity. A strain Σ1 provides, with a probability φ = φ 2 1 , full cross-immunization against a strain Σ2. b Model with attenuating immunity. All individuals who underwent infection by Σ1 are partly protected against Σ2, such that their infection rate is reduced. c Rolling strains with sterilizing cross-immunity. Several variants of a same pathogen hit a population after each-other, each providing cross-immunity against future strains with probabilities φ t i n * 1 . While n * 1 marks the peak of Σ 1 infections, more incidental transmission is possible until it wanes off completely. It is possible to compute the total population fraction, r ∞ 1 , that will eventually undergo infection if the outbreak plays out naturally [25] : where W (·) is Lambert's W function and s 0 1 and r 0 1 are initial conditions as introduced above (for Σ 0 : s 0 1 1, r 0 1 = 0). Let us assume that, well after the first outbreak has played out, a second strain, Σ 2 , arrives which follows similar equations but with parameters (β 2 , γ 2 ). This strain will be subjected to similar dynamics depending on whether the corresponding threshold (s * 2 ≡ γ 2 /β 2 , n * 2 ≡ 1 − γ 2 /β 2 ) has been reached. How might crossimmunity provided by Σ 1 alter this condition? We introduce this effect in two different ways. The first one assumes that Σ 1 provides sterilizing immunity with a probability φ (Fig. 1a) . This means that, out of all the individuals who underwent infection with Σ 1 , a fraction φ of them cannot become infected by (and, accordingly, cannot propagate) Σ 2 . The second kind of cross-immunity ( Fig. 1b) assumes that those who underwent infection with Σ 1 can become infected by Σ 2 , but they do so at a reduced rate, β 2 /σ (with σ > 1). If they become infected, they are as contagious as usual. We refer to this as attenuating immunity. We will use estimates of parameters from actual SARS-CoV-2 strains to illustrate relevant information that can be extracted from our model. Let us notate the original SARS-CoV-2 strain as Σ 0 and some of its variants of concern as Σ α , Σ β , Σ δ , and Σ o (with the subscripts carrying the standard names). We will use the same Greek-letter underscripts (and 0) to label model parameters when referring to SARS-CoV-2 strains, while we will use numbers 1 and 2 when referring to variants in the model. To study longer-term effects of cross-immunity, we wish to learn how strains more distant in time might affect statistical features of outbreaks-such as their average size (measured as the population fraction they infect), typical SIR parameters of successful strains, or time between successive outbreaks of a given magnitude. We want to investigate how these properties are changed by the extent of immunizing memory across the population or by evolutionary mechanisms that might favor more dissimilar variants. We try to do so with the simplest model that builds upon insights from the previous section. We will model sterilizing immunity only. To do so, we just need to keep track of individuals recovered from each strain-as will become clear later. To build a similar model for attenuating immunity we would need to keep track of individuals that might undergo infection with . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Sterilizing cross-immunity between two successive strains. a Minimum cross-immunity needed for Σ1 to prevent Σ2 outbreaks as a function of Σ1-recovered individuals, r ∞ 1 , and Σ2-herd-immunity threshold, n * 2 . The white line marks when outbreaks become unavoidable (Σ1 cannot generate enough protection). b Same, as a function of basic reproduction numbers, R 0 1 and R 0 2 . The white curve (mapped non-linearly into this representation) again bounds unavoidable outbreaks. A vertical blue line marks R 0 = 3.15, a robust estimate of R 0 for the original SARS-CoV-2 virus [22, 23] . c Same, as a function of Σ2 model parameters, β2 and γ2; assuming R 0 1 = 3.15. Unavoidable outbreaks appear confined to a small region (lower-right corner). d-f Cross-immunity in SARS-CoV-2. d Protection if the original virus, Σ0, had played out its natural SIR cycle. The black curve (cross-section of panel b with R 0 = 3.15) separates all variants that would have been avoided in this scenario (white region). The horizontal red line marks an estimated level of Σ0-elicited protection against Σ β [24] . If Σ0 had played out naturally before Σ β hit, Σ β outbreaks would have been halted unless R 0 β > ∼ 5. e Protection assuming 100% vaccination rate (solid black curve), and assuming 'just enough' Σ0 infections before its remission (i.e. only n * 1 people got infected, dashed black curve). Protection as in d (dashed gray curve) is shown as reference. Red lines mark Σ0-elicited cross-immunity estimated against Σα (solid), Σ δ (dashed), and Σo (dotted). Both Σα and the deadly Σ δ would have been prevented in fully vaccinated populations unless they had and impressive R 0 > several strains and might acquire different levels of protection. Also, while we have a closed form for r ∞ in the SIR model (Eq. 5, which will become important), we do not have a similar expression for the model that results from attenuated immunity. Let us assume a series of strains, [Σ 1 , Σ 2 , . . . , Σ t , . . . ], rolling one after another (Fig. 1c) . At any time, t, there is only one active variant, Σ t , such that two outbreaks never overlap. We are hence assuming that the duration of an outbreak constitutes a unit of time. We also assume that these rolling strains are variants of a same pathogen-as it happens in COVID-19 waves. At a microscopic level, viral sequences mutate, resulting in new strains that descend from each-other with slight pheno-type variations. We model this relatedness by generating SIR parameters of successive variants from an uncorrelated, unbiased random walk: Here, η β and η γ are stochastic variables drawn from a Gaussian distribution with mean 0 and standard deviations σ β and σ γ respectively (in most simulations, σ β/γ = 0.1). Both β and γ are positive, thus the random walk is bounded from below. We also set arbitrary upper bounds at β + = 10, γ + = 10 to prevent unrealistically high infectivity and recovery rates. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint FIG. 3 Effects of attenuating cross-immunity. a-c Same as in 2a-c. The cross-immunity parameter now spans σ ∈ [1, ∞), and has been cropped to aid the visualization (note differences in color bars, which were adjusted to enhance the displayed gradients). Solid (black or white) curves indicate σ = 2. Dashed (black or white) curves indicate σ = 5. Dotted white curves indicate σ = 10. Red curves indicate the boundary beyond which no level of cross-immunity can avoid new outbreaks. These regions match those for sterilizing immunity in all parameter spaces, anticipating a mapping between both cross-immunity mechanisms. d, e Same as in 2d, e. d The dashed vertical line marks the level of protection achieved by the original SARS-CoV-2 virus against the β variant. To achieve the same level of protection with attenuating immunity, we seek the intersection of this vertical line with the black curve (which is, in turn, a vertical cut of panel b with R 0 = 3.15). f Eq. 17 (black curve) formalizes the equivalence between both models. Levels of attenuating immunity needed to match estimated sterilizing immunity of real SARS-CoV-2 variants can be read from the intersections of horizontal red lines and the corresponding vertical marks. Eq. 5 allows us to compute r ∞ t (the fraction of nonsusceptible population after Σ t completed its natural cycle). Since we consider rolling strains with crossimmunity, a part of this fraction (r 0 t , which we calculate below) consists of people immunized by earlier strains. This r 0 t works as an initial condition. Another part of r ∞ t consists of people who properly underwent infection with Σ t . Let us note this later fraction of the total population asr ∞ t . These are the people who might gain cross-immunity thanks to Σ t . Let any earlier, successful strain, Σ i , provide crossimmunity against later variants, Σ j>i . This happens with a likelihood φ j i ∈ [0, 1] for each recovered individual. Thus, due to Σ i , a fractionr ∞ i φ j i of the population is immunized against Σ j when it hits. Similar fractions of cross-immunized population will be generated by other variants that preceded Σ j . These fractions might or might not overlap-i.e. a person might acquire sterilizing immunity against Σ j from one, two, or more different ancestors. To calculate r 0 j , we need to compute the fraction of population who acquired cross-immunity from any (at least one) strain that preceded Σ j . Due to the possible overlaps, this becomes cumbersome. It is easier to note that the protected population is the complementary of the population who did not get immunity from any strain. This can be written as an equation more easily: When Σ j arrives, we can plug in this initial condition to the SIR equations to check the additional fraction of immunized population that Σ j produces before it remits spontaneously:ñ * Ifñ * j ≤ 0, Σ j fails to spread in the population. Ifñ * j > 0, Σ j causes an outbreak. The amount of people infected by this new variant can again be calculated through Eq. as the magnitude or size of the Σ j outbreak. For cross-immunity, relatedness between strains is important. We model it using random walks again, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint now bounded within φ j i ∈ [0, 1] (Fig. 1d) . Say that Σ i produces an outbreak; but that the next strains, Σ i+1 , . . . , Σ j−1 , fail to spread; until Σ j results in an outbreak again. We kick-start a random walk at t = i that begins with φ i i = 1 (i.e. Σ i offers full protection against itself). For each successive strain, whether they produce an outbreak or not, we keep track: with η φ a stochastic Gaussian variable of mean 0 and standard deviation σ φ (usually σ φ = 0.1). Non-spreading variants do not produce cross-immunity, hence we do not start random walks for any of them. After Σ j unfolds, it does generate cross-immunity, and a new random walk is started with φ j j = 1. Protection against future strains might be gained from either Σ i or Σ j now, thus the former random walk remains active. Nothing forces these random walks to offer less cross-immunity over time, meaning that a strain might offer higher protection for variants further in the future than for closer ones. This is counter-intuitive, but it has happened for SARS-CoV-2 waves as Σ 0 offered higher cross-immunity against Σ δ than against Σ α and Σ β (Fig. 3 ) [24] . We should keep a random walk running for each successful strain, but carrying so many parallel processes is computationally expensive. To solve this problem, we introduce another relevant ingredient that is well grounded in biology and epidemic dynamics-population renewal. We assume that, at each time unit (i.e. after each new strain's cycle), a fraction δ of the population is renewed. This has no effect for people who did not acquire immunity-as they are replaced by new people who are not immunized either. On the other hand, the population fraction that underwent infection by Σ i becomes a time-dependent decaying variable: To ease the computational load, we stop tracking any variant whoser ∞ i (t) falls below 1% of population size. The parameter δ introduces a measure of immune memory across the population. If δ = 1, no memory is ever left of successful strains. We obtain a trivial series of SIR outbreaks with parameters drawn from a random walk. For δ < 1, the population keeps a memory of the epidemics it endured-thus affecting which future strains can possibly succeed and, hence, which model parameters are likely to generate outbreaks. A. Cross-immunity between two consecutive strains The mechanism for sterilizing cross-immunity leaves the equations for the second strain (Eqs. 1) unchanged, but alters their initial conditions-a population fraction φr ∞ 1 starts as non-susceptible (Fig. 1a) . The derivative of infections at the second outbreak onset reads: By equating this to zero, we find a threshold that determines whether sterilizing cross-immunity can prevent the outbreak: If φ > φ * , Σ 1 provides enough sterilizing cross-immunity. From the beginning, Σ 2 cannot find sufficient hostsany impending outbreak remits spontaneously. If φ < φ * , enough susceptible individuals remain for Σ 2 to take hold. Fig. 2a shows the amount of cross-immunity needed to avoid the second outbreak, φ * , as a function of n * 2 and r ∞ 1 . For n * 2 > r ∞ 1 , φ * > 1; hence the spread of Σ 2 becomes unavoidable. φ * only depends on model parameters through the basic reproduction numbers R 0 1/2 . This makes it easier to use empirical estimates from real outbreaks. Fig. 2b shows φ * as a function of R 0 1 and R 0 2 . The condition for unavoidable outbreaks (n * 2 > r ∞ 1 ) becomes nonlinear in this representation. A vertical blue line marks R 0 0 = 3.15, a robust estimate for the original variant, Σ 0 , of the SARS-CoV-2 virus [22, 23] . This allows us to visualize φ * as a function of infectivity, β 2 , and recovery rates, γ 2 , of potential variants for this actual virus (Fig. 2c) . The line marking R 0 0 = 3.15 (Fig. 2b) does not intersect n * 2 = r ∞ 1 within the shown R 0 2 range. This means that all SARS-CoV-2 variants with R 0 2 < 10 could have been blocked if Σ 0 had played out completely and it offered enough sterilizing cross-immunity. This becomes more clear in Fig. 2d (which plots the relevant crosssection of Fig. 2b ). For each possible new variant with R 0 2 < 10, and assuming Σ 0 played out fully, infecting a population fraction r ∞ 0 , it exists a feasible level of sterilizing cross-immunity, φ * R 0 2 < 1 (black curve), that would prevent any new outbreaks. In Fig. 2d , a horizontal red line marks the estimated protection that Σ 0 offers against Σ β [24] . (Actually, the likelihood that Σ 0 infection prevented symptomatic Σ β infection-hence a best-case scenario.) The intersection of this protection level with φ * R 0 2 (dashed blue line) indicates all the variants that Σ 0 would have protected against if it had played out naturally (infecting a population fraction r ∞ 0 ). Roughly, any variant with R 0 2 < ∼ 5 would have been prevented with this level of cross-immunity. We can use similar plots to evaluate whether new variants should worry us given levels of cross-immunity elicited by a vaccine and fractions of vaccinated population. In Figs. 2e, f, horizontal red lines mark sterilizing protection (estimated as above [24] ) provided by Σ 0 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. against variants Σ α (solid), Σ δ (dashed), and Σ o (dotted). We assume that vaccines prompt a same crossimmune response. The fraction of vaccinated population enters Eq. 12 as an initial condition, instead of r ∞ 1 , resulting in altered φ * R 0 2 curves. Fig. 2e shows two extreme cases: (i) just enough people to stop Σ 1 was vaccinated (dashed curve) and (ii) the whole population was vaccinated (solid curve). Fig. 2f shows φ * R 0 2 depending on vaccination rates across the world as of Oct. 16, before the deadly Σ δ wave hit most of the represented countries. Estimates of R 0 δ range between 3.2 and 6 [26] [27] [28] . In this best-case scenario, Σ δ could have been avoided by fully vaccinated populations. Cross-immunity offered for Σ o would not have been enough to stop it unless its basic reproduction number were very low (which, likely, was not [29, 30] ). Our second mechanism is closer to implementations of cross-immunity in the literature [5, [19] [20] [21] . Individuals who underwent Σ 1 infection remain susceptible during a Σ 2 outbreak, but their infection rate is attenuated:β 2 ≡ β 2 /σ, with σ > 1. This entails both a change of initial conditions and of model equations for Σ 2 outbreaks (Fig. 1b) : s 2 (t) represents the fraction of susceptible individuals with attenuated infection rate, while s 2 (t) are regular susceptible hosts. Population is normalized again, making one of these equations redundant. We check when Σ 2 stops spreading: We get a herd-immunity threshold for the weighted sum of susceptible individuals: Ifs 2 /σ + s 2 < 1/R 0 2 , then . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint Σ 2 cannot cause enough new infections in average-the outbreak remits spontaneously. Ifs 2 /σ + s 2 > 1/R 0 2 , the outbreak grows until the susceptible populations become depleted enough. Boths 2 (t) and s 2 (t) decrease over time always, thus they can only pass this threshold once-i.e. these dynamics cannot bounce back up. We substitute the initial conditions after Σ 1 to check whether Σ 2 is spontaneously halted at its onset. A population fraction r ∞ 1 starts inS, while 1 − r ∞ 1 start out as regular susceptible individuals: By solving for σ, we find a threshold that determines whether attenuating cross-immunity can prevent the outbreak: If σ is larger than this threshold, then the level of attenuation is enough as to halt a Σ 2 outbreak. For n * 2 → 0, σ * → 1; thus any attenuation is enough to halt Σ 2 . To reach this limit, β 2 itself must become very small-hence explaining why any σ > 1 would suffice. On the opposite end (n * 2 → r ∞ 1 ), attenuating crossimmunity cannot be achieved since σ * → ∞. Eq. 16 has a singularity at n * 2 = r ∞ 1 , after which σ * becomes negative (Fig. 3a) , and is thus meaningless for n * 2 > r ∞ 1 . But we know that, due to parsimony, there is no level of attenuation that can prevent outbreaks in that regime. Thus, we recover the same limit condition as for sterilizing cross-immunity. These results, again, only depend on model parameters through the basic reproduction numbers. Fig. 3b shows σ * in the R 0 1 − R 0 2 plane. We mark the boundary of unavoidable outbreaks (n * 2 = r ∞ 1 , red) and the estimate R 0 0 = 3.15 for the original SARS-CoV-2 strain (blue). By holding this value fixed, we can represent σ * 2 as a function of γ 2 and β 2 (Fig. 3c) . Fig. 3d plots the cross-section of Fig. 3b with R 0 0 = 3.15. The black curve marks σ * R 0 2 , the attenuation level needed to halt new SARS-CoV-2 strains as a function of R 0 2 . The dashed blue line marks the separation between strains that could and could not be halted by sterilizing cross-immunity. The red horizontal line uses σ * R 0 2 to track back the level of attenuation that would offer a similar protection: Σ 2 infection following Σ 0 recovery should be ∼ 7 times less frequent than natural infection. Similar translations are possible for scenarios with population immunized through vaccination (Fig. 3e) . We make this equivalence between models rigorous by demanding that the n * 2 featured in Eqs. 12 and 16 take the same value, obtaining: Fig. 3f shows this mapping between models. We mark levels of attenuating immunity needed to match sterilizing immunity for SARS-CoV-2 variants. Eq. 17 does not depend on the fraction of immunized populationsuggesting a deep correspondence between both immunizing mechanisms. Model dynamics alternate (i) long periods of no activity with periods of (ii) sparse and (iii) very frequent outbreaks. The former happen when the random walk is confined to the upper-left half of the (β, γ) plane (no-epidemics region, Fig. 2c ). We name this area Z 0 , and we call Z 1 to the lower-right hemiplane (where SIR outbreaks always happen). If the random walk spends enough time in Z 0 , all memory about earlier outbreaks is lost. Fig. 4a1 shows model behavior during sparse outbreaks. Such sparsity might be due to the random walk dwelling near the Z 0 − Z 1 boundary. Decay dynamics following population renewal stand out. The fraction of protected population remains similar to outbreak magnitudes. Fig. 4a2 shows model behavior during frequent outbreaks. This regime corresponds to deep dives into Z 1 . New successful strains appear at every time step. The dynamics are dominated by the accumulated immunized population. The fraction of protected population is much larger than the average outbreak size. We are interested in statistical properties of successful strains over long periods. Therefore we ran our model for 10 6 time steps under different experimental conditions. Fig. 4b shows average outbreak magnitude as a function of model parameters (β, γ) with δ = 0.1. Outbreak sizes are greatly reduced with respect to SIR processes without cross-immunity (Sup. Fig. 1f ). Fig. 5a shows that outbreak size mitigation depends linearly on population renewal. Both with (Fig. 4b) and without (Sup. Fig. 1f ) cross-immunity, outbreak magnitude becomes larger the deeper we dive into Z 1 . But only with crossimmunity, relatively large outbreaks stand out around the lower-left corner of parameter space, near the Z 0 −Z 1 boundary. This becomes more evident when plotting the largest outbreak as a function of model parameters (Fig. 4c) . With cross-immunity, the largest outbreaks happen exclusively in this small region, while larger outbreaks happen for broader combinations of parameters without cross-immunity (Sup. Fig. 2f) . Indeed, if the random walk reaches deep into Z 1 , it will follow a long path with frequent successful strains, thus accumulating immunized population unless renewal is high. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. Notwithstanding this localization of large outbreaks for small renewal (hence large cross-immunity), the average β and γ appear relatively constant for varying δ (Fig. 5b) . This suggests that, overall, cross-immunity prevents (or weakens) outbreaks similarly throughout parameter space. Upon close inspection, these averages actually change slightly. Dotted lines in Fig. 5b help visualize that γ(δ = 0.1) < γ(δ = 1). This effect becomes more salient in the basic reproduction number (Fig. 5c , since R 0 = β/γ has γ in the denominator, hence amplifying trends). R 0 stands for a growth factor, thus its variation has an exponential effect in the dynamics. Changes in this parameter with respect to SIR without crossimmunity stand out in distributions of R 0 for successful strains (Fig. 4d) . Distributions for both δ = 0.1 (black) and δ = 1 (red) present similar tails, but their peaks (at 1 and ∼ 1.2 respectively) differ. A population's current immunization state constrains the characteristics of the next, possible successful strains. Fig. 4e shows how a given amount of protected population limits the magnitude of possible outbreaks. This effect wanes as increased population renewal erases the immune memory (Sup. Fig. 3) . A current immunization state also influences likely increases in model parameters, β and γ. The underlying random-walk is unbiased, but the distribution of β and γ increases becomes asymmetric (Fig. 4f) . If a random-walk step increases β and decreases γ (deeper into Z 1 ), the strain becomes more aggressive, likely producing an outbreak despite existing cross-immunity. If the step goes in the opposite direction (towards Z 0 ), the resulting, less-aggressive strain might be averted by population immunity. Then, the next outbreak shall arrive when memory is lost and the random walk has drifted further away. This asymmetry is lost as population renewal increases (Sup. Fig. 4) . Fig. 4f also shows frequent events along the diagonal ∆β = ∆γ. These events result from returns from Z 0 into Z 1 (reentry points can be arbitrarily far apart along the Z 0 −Z 1 boundary). Average time between consecutive outbreaks of a given size (Inter-Event Times, IET ) grows monotonously and include a stark non-linearity for any δ = 1 (Fig. 5d) . The step-like behavior suggests a singular, δ-dependent outbreak size, r * (δ), such that larger events very swiftly become very rare (roughly, at the intersection of IET curves with the dashed black line, Fig. 5d ). This invites a qualitative distinction between epidemic (frequent, small magnitude) and pandemic (rare, larger size) dynamics that emerges naturally out of cross-immunity (note that r * (δ = 1) = 1, thus events of all sizes are fairly equally frequent in memory-less SIR). We studied simple models of cross-immunity to see how it affects dynamics in short-and long-term scopes. Starting from the SIR equations (a cornerstone of epi-. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint demic dynamics), we added as little as possible to include cross-immunity, avoiding additional dynamic ingredients (e.g. reinfection, strain coexistence and competition, population structure, etc.) present in other cross-immunity models [5, [19] [20] [21] . Regarding short-time effects, we investigated two mechanisms: (i) A past strain might provide sterilizing immunity against a future strain. Each recovered individual has a chance of becoming sterile to the second pathogen. (ii) A past strain does cause attenuating immunity against a future strain. All affected individuals might become infected by the second variant, but at a lower rate. Both mechanisms modify the thresholds of herd immunity of the standard SIR model. Our thresholds depend on the magnitude of the first outbreak, and on the likelihood of sterilization (in the first case) or on the level of attenuation (in the second). These thresholds result in intuitive maps that separate which future strains can and cannot cause outbreaks. These plots also asses whether vaccination rates and vaccine efficiency suffice to stop new variants-a point illustrated with actual data from SARS-CoV-2 waves. The reliability of these charts depends on accurate estimates of vaccine efficiency and each variant's basic reproductive number. Measuring these parameters might require that a strain spreads throughout a population (which would preempt the utility of our approach). However, lab experiments can compare emerging variants to earlier ones, rendering quick proxies to build preliminary maps for variants of concern. Discussion regarding herd protection usually considers sterilizing immunity alone. Hopes of herd immunity against SARS-CoV-2 often faltered as it became evident that vaccines would not be sterilizing [7] . Following the same logic, several research strategies bet on sterilizing vaccines as a more definitive way out of this and other pandemics [31] [32] [33] [34] [35] . Our results show that attenuating immunity also modify SIR thresholds substantially. We further prove an equivalence (encapsulated by Eqs. 17) between both immunity mechanisms, offering new hope in dealing with epidemic scenarios. In a relevant perspective, Lipsitch et al. [7] reviewed possible epidemiological scenarios for the COVID-19 pandemic depending on cross-reactive activity developed by different kinds of T-cells localized in distinct tissues. Three cases are studied: (i) reduction of lung burden, in which antibodies only mitigate the severity of latestage COVID disease; (ii) accelerated antibody response, which mitigates the disease and shortens its infectivity period; and (iii) fast and strong response in the upper respiratory tract (URT), which would halt within-organism spread swiftly, and which comes the closest to sterilizing immunity. Implications to the epidemiological dynamics are discussed for all cases, but only in the third one (which the authors consider the less likely) do they expect a reduced herd-immunity threshold. We should revise all three scenarios in a more optimistic note. On the one hand, even if it is unlikely that URT response is prompt and strong enough as to be sterilizing, it might still result in a reduced infectivity rate. Hence, even a weak response of the third kind could trigger our mechanism of attenuating cross-immunity. On the other hand, both (i) and (ii) cases result in reduced viral load and duration of the infective process, lowering the chances that cross-immunized individuals infect others. This effect is different from the one that we model, but it too results in a reduced infectivity (like β/σ) for a population subset. Based on our results, we expect changes in the herd-immunity thresholds in all scenarios. Herd immunity is a stark non-linear effect that causes spontaneous remission of epidemic outbreaks. Of all epidemiological consequences of cross-immunity discussed in [7] , more lenient thresholds is the most impactful and desired possibility. Regarding long-time effects, we simulated a succession of strains rolling one after the other and offering crossimmunity over longer periods of time. The length of these periods is loosely controlled by population renewal-the smaller it is, the larger the population-wide effect of cross-immunity. Increased cross-immunity reduces the average epidemic magnitude linearly. When population renewal is small, the largest outbreaks become confined to a small region of parameter space-while, in memory-less SIR processes, large outbreaks happen for broad combinations of infectivity and recovery rates. Thus, cross-immunity alters the phenotype of strains from which extreme events can be expected. In our model, a natural distinction appears between frequent, relatively small outbreaks and rare, relatively large episodes. This distinction (not present in SIR processes) invites an emergent classification of "epidemic" and "pandemic" events. Existing cross-immunity levels constrain which model parameters (hence which strain phenotypes) might produce an outbreak next. Our model (built upon an unbiased random walk) has no explicit preference regarding whether infectivity and recovery rates should increase or decrease as strains roll out. Cross-immunity induces an asymmetry favoring more infective strains with longer recovery rates. There is ample room for future exploration regarding this last point. We do not distinguish between recovered and deceased individuals, nor do we track disease severity. Very likely, pathogens causing more serious illness, with increased death tolls, will induce stronger (cross-)immunity. This should further change where, in parameter space, large outbreaks are expected; as well as the phenotypes into which an active pathogen (e.g., currently, SARS-CoV-2) might evolve as constrained by cross-immunity. We modeled one of these aspects using random walks biased towards less averted strains (i.e., lower φ; not shown). We did not find qualitative differences from the behavior reported in this paper. This indicates that more ingredients are needed to expand the model in this direction. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint A limitation of our model with rolling strains is that we only implement sterilizing immunity, as attenuating immunity poses some computational challenges. However, we can use the equivalence captured by Eq. 17 to find out what strains would have had similar effects using our second mechanism. A more general limitation is in assuming SIR equations throughout. More factors, both biological (incubation period, super-spreaders, etc.) and social (confinement, fear, social distancing, etc.), affect the empirical parameters from SARS-CoV-2 analyzed. Our charts should be taken as limit cases. It is noteworthy, however, that we can produce meaningful tools for a real, ongoing epidemic process-this should be furthered. Note also that most of these factors would slow viral spread compared to actual SIR processes. Thus, more accurate models should result in more lenient thresholds. The SARS-CoV-2 pandemic made explicit a very important limitation of SIR-like models: while they reveal overall trends and the existence of phenomena such as herd-immunity thresholds, they are useless to predict even the most salient aspects of a specific outbreak (namely, its magnitude and duration) [10] . We explore our models with the same philosophy, avoiding specific predictions and seeking broad qualitative changes induced by cross-immunity. To overcome the problems of compartmental models, and allow us to apply them in more realistic situations, two strategies are being explored: (i) To produce more detailed equations, that include as many aspects as possible. In this approach, cross-immunity should be indispensable, as the interactions between SARS-CoV-2 variants illustrate. (ii) To gather data at a microscopic level, registering sub-regional incidences, capturing population movements across road or airplane networks [14, 18, 36, 37] , or quantifying the structure of social contact networks (often depending on age and cultural aspects of a given group) [38] . Regarding prediction, these details might work similarly to how abundant, localized data alleviates the chaotic weather dynamics-but gathering such low-level data in human behavior has a distinct ethic dimension that makes it problematic. Regarding qualitative aspects of epidemic dynamics, such microscopic data might help us understand where (in a spatial or social network) (cross-)immunity could be more effectiveand hence design, e.g., smart quarantine or vaccination strategies [17, 36] . We are indebted to Susanna Manrubia for her support during this research, and for the lively discussions that guided and improved our work. LFS wishes to acknowledge Jorge Mira, Alberto P Muñuzuri, Iván Area, Juan J Nieto, Pablo Boullosa, Adrián Garea, and Alejandro Carballosa for the initial discussions that fostered this work. Both IA-D and LFS were supported by grant PID2020-113284GB-C21, funded by MCIN/AEI/10.13039/501100011033. LFS has received funding from the Spanish National Research Council (CSIC) and the Spanish Department for Science and Innovation (MICINN) through a Juan de la Cierva Fellowship (IJC2018-036694-I), and from the Spanish "Instituto de Salud Carlos III and the Ministerio de Ciencia e Innovación" through the research grant COV20/00617 entitled PREDICO. The Spanish MICINN has also funded the "Severo Ochoa" Centers of Excellence distinction for the CNB, where this research was carried out (grant SEV 2017-0712), and the special grant PIE 2020-20E079 (awarded to the CNB) entitled "Development of protection strategies against SARS-CoV-2". . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For small enough population renewal (i.e. large cross-immunity memory), the largest outbreaks are confined to a small region of parameter space (bottom left, near the Z0 − Z1 border). When cross-immunity is removed (as δ → 1), very large outbreaks happen for almost any combination of model parameters. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273361 doi: medRxiv preprint From vaccines to memory and back Antigenic diversity thresholds and the development of AIDS Viruses as Complex Adaptive Systems Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans Localized contacts between hosts reduce pathogen diversity SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 Cross-reactive memory T cells and herd immunity to SARS-CoV-2 Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts A contribution to the mathematical theory of epidemics The turning point and end of an expanding epidemic cannot be precisely forecast Infectious Diseases of Humans: Dynamics and Control Epidemics and percolation in small-world networks Modeling Infectious Diseases in Humans and Animals Risk of secondary infection waves of COVID-19 in an insular region: the case of the Balearic Islands Modeling COVID-19 dynamics in Illinois under nonpharmaceutical interventions Individual risk-aversion responses tune epidemics to critical transmissibility (r = 1) Manrubia S. Vaccination strategies in structured populations under partial immunity and reinfection Arenas A, Gómez-Gardeñes J. Modeling communicable diseases, human mobility, and epidemics: A review Epidemiologic interference of virus populations The dynamics of cocirculating influenza strains conferring partial cross-immunity Epidemiological models with age structure, proportionate mixing, and cross-immunity An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Metaanalysis and sensitivity analysis Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant Analytical solution of the SIRmodel for the temporal evolution of epidemics. Part A: time-independent reproduction factor Transmission dynamics of an outbreak of the COVID-19 Delta variant B.1.617.2-Guangdong Province Global vulnerabilities to the COVID-10 variant B.1.617.2. SUERF policy Herd immunity induced by COVID-19 vaccination programs to suppress epidemics caused by SARS-CoV-2 wild type and variants in China Relative reproduction number of SARS-CoV-2 Omicron (B.1.1.529) compared with Delta variant in South Africa Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models Development of subunit vaccines that provide high-level protection and sterilizing immunity against acute inhalational melioidosis Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine Prevention of tuberculosis in macaques after intravenous BCG immunization Sterilizing immunity against COVID-19: Developing helper T cells I and II activating vaccines is imperative Optimal control of the COVID-19 pandemic: controlled sanitary deconfinement in Portugal Risk evaluation at municipality level of a COVID-19 outbreak incorporating relevant geographic data: the study case of Galicia